KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Total Liabilities (2016 - 2025)

BeOne Medicines (ONC) has disclosed Total Liabilities for 11 consecutive years, with -$4.1 billion as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 20.18% to -$4.1 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.1 billion, a 20.18% decrease, with the full-year FY2024 number at $2.6 billion, up 102.39% from a year prior.
  • Total Liabilities was -$4.1 billion for Q3 2025 at BeOne Medicines, down from $2.5 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $2.6 billion in Q4 2024 to a low of -$5.8 billion in Q1 2022.
  • A 5-year average of -$520.9 million and a median of $1.3 billion in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 175.29% in 2021, then crashed 281.72% in 2023.
  • BeOne Medicines' Total Liabilities stood at $2.4 billion in 2021, then crashed by 54.31% to $1.1 billion in 2022, then grew by 16.51% to $1.3 billion in 2023, then surged by 102.39% to $2.6 billion in 2024, then crashed by 259.51% to -$4.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Total Liabilities are -$4.1 billion (Q3 2025), $2.5 billion (Q2 2025), and -$3.5 billion (Q1 2025).